Freeform Search

Term Displ		Number 1	
***************************************	Search History		
DATE:	Friday, May 14, 2004 Printable Copy Create Case		
Set Name side by side	Query	<u>Hit</u> Count	Set Name result set
DB=B	PGPB,USPT; PLUR=YES; OP=AND		
<u>L3</u>	11 with 12	10	<u>L3</u>
<u>L2</u>	(treat\$ or protect\$) near6 (neural adj tissue or brain or cns or central adj nervous adj system or cerebellum or cerebrum)	16502	<u>L2</u>
<u>L1</u>	(neuronal or neural) near3 progenitor adj cell	481	<u>L1</u>

END OF SEARCH HISTORY

Generate Collection Print

Search Results - Record(s) 1 through 10 of 10 returned.

- 1. 20040034049. 01 Apr 03. 19 Feb 04. Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells. Okawa, Shigenori, et al. 514/278; 514/409 A61K031/4747. 2. 20030223972. 14 Feb 03. 04 Dec 03. Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells. Goldman, Steven A., et al. 424/93.21; 435/368 435/456 435/458 435/459 A61K048/00 C12N005/08 C12N015/86 C12N015/88 C12N015/87. 3. 20030203844. 18 Sep 02. 30 Oct 03. Treatment of central nervous system disorders. Delfani, Kioumars, et al. 514/12; A61K038/18. 4. 20030082160. 24 Sep 02. 01 May 03. Differentiation of whole bone marrow. Yu, John S., et al. 424/93.21; 435/368 A61K048/00 C12N005/08. 5. 20030049234. 18 Mar 99. 13 Mar 03. DISCOVERY, LOCALIZATION, HARVEST, AND PROPAGATION OF AN FGF2 AND BDNF-RESPONSIVE POPULATION OF NEURAL AND NEURONAL PROGENITOR CELLS IN THE ADULT HUMAN FOREBRAIN. GOLDMAN, STEVEN A., et al. 424/93.21; 435/368 A61K048/00 C12N005/08.
- 6. 20030003090. 23 May 02. 02 Jan 03. Directed in vitro differentiation of marrow stromal cells into neural cell progenitors. Prockop, Darwin J., et al. 424/93.21; 435/368 A61K048/00 C12N005/08.
- 7. 20020037281. 25 May 01. 28 Mar 02. Methods of transducing neural cells using lentivirus vectors. Davidson, Beverly L., et al. 424/93.21; 435/368 435/456 C12N015/867 A61K048/00 C12N005/08.
- 8. 20010024827. 08 May 01. 27 Sep 01. Neuronal progenitor cells and uses thereof. Luskin, Marla B. 435/375; 435/6 C12Q001/68 C12N005/08.
- 9. 6251669. 05 Jan 98; 26 Jun 01. Neuronal progenitor cells and uses thereof. Luskin; Marla B.. 435/375; 424/93.21 435/6 435/69.1. C12N005/00 C12N005/02 C12Q001/68 C12P021/06 A61K048/00.
- 10. 5753505. 06 Jul 95; 19 May 98. Neuronal progenitor cells and uses thereof. Luskin; Marla B.. 435/375; 424/93.21 435/6 435/69.1. C12N005/00 C12N015/09 A61K048/00.

Generate Collection Print

Terms	Documents
L1 with L2	10

Prev Page Next Page Go to Doc#

e e e

=> d his

L1

L3

(FILE 'HOME' ENTERED AT 15:02:07 ON 14 MAY 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 15:02:23 ON 14 MAY 2004

- 3012 S (NEURONAL OR NEURAL) (3A) PROGENITOR (W) CELL
- L2 66482 S (TREAT? OR PROTECT?) (6A) (NEURAL(W) TISSUE OR BRAIN OR CNS OR C
 - 73 S L1 AND L2
- L4 13 S L1(9A)L2
- L5 11 DUP REM L4 (2 DUPLICATES REMOVED)
- L6 47 DUP REM L3 (26 DUPLICATES REMOVED)

=> d au ti so 21-47 16

- L6 ANSWER 21 OF 47 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
- AU Chen J L; Li Y; Wang L; Lu M; Chopp M (Reprint)
- TI Caspase inhibition by Z-VAD increases the survival of grafted bone marrow cells and improves functional outcome after MCAo in rats
- SO JOURNAL OF THE NEUROLOGICAL SCIENCES, (15 JUL 2002) Vol. 199, No. 1-2, pp. 17-24.

Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS.

ISSN: 0022-510X.

- L6 ANSWER 22 OF 47 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
- AU Jarman, R. G. [Reprint Author]; Freed, C. R. [Reprint Author]
- TI HUMAN NEURAL PROGENITOR CELLS SHOW NORMAL VENTROLATERAL MIGRATION IN ORGAN CULTURES OF HUMAN EMBRYONIC MESENCEPHALON.
- SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 726.7. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience. Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
- L6 ANSWER 23 OF 47 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
- AU Stauffer, W. R. [Reprint Author]; Fellows-Mayle, W. [Reprint Author]; Niranjan, A. [Reprint Author]; Tyler-Kabara, E. [Reprint Author]; Hong, C. S.; Glorioso, J.; Gobbel, G. T. [Reprint Author]
- TI BRAIN IRRADIATION ENHANCES SURVIVAL OF NEURAL PROGENITOR ALLOGRAFTS TRANSPLANTED INTO NORMAL AND TUMOR-BEARING BRAINS.
- SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 237.14. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience. Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
- L6 ANSWER 24 OF 47 MEDLINE on STN
- AU Okano H
- TI Neural stem cells: the basic biology and prospects for brain repair.
- SO Rinsho shinkeigaku. Clinical neurology, (2001 Dec) 41 (12) 1036-40. Journal code: 0417466. ISSN: 0009-918X.
- L6 ANSWER 25 OF 47 MEDLINE on STN

DUPLICATE 5

- AU Vaccarino F M; Ganat Y; Zhang Y; Zheng W
- TI Stem cells in neurodevelopment and plasticity.
- Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, (2001 Dec) 25 (6) 805-15. Ref: 104 Journal code: 8904907. ISSN: 0893-133X.
- L6 ANSWER 26 OF 47 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
- AU Viktorov I V (Reprint)
- TI Stem cells of mammalian brain: Biology of the stem cells in vivo and in vitro

- SO BIOLOGY BULLETIN, (NOV-DEC 2001) Vol. 28, No. 6, pp. 544-552. Publisher: MAIK NAUKA/INTERPERIODICA, C/O KLUWER ACADEMIC-PLENUM PUBLISHERS, 233 SPRING ST, NEW YORK, NY 10013-1578 USA. ISSN: 1062-3590.
- L6 ANSWER 27 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN
- AU Kitagawa, Kazuo; Matsumoto, Masayasu; Hori, Masatsuqu
- TI Protective and regenerative response endogenously induced in the ischemic brain
- SO Canadian Journal of Physiology and Pharmacology (2001), 79(3), 262-265 CODEN: CJPPA3; ISSN: 0008-4212
- L6 ANSWER 28 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 6
- AU Lu, Chengbiao; Fu, Weiming; Mattson, Mark P.
- TI Telomerase protects developing neurons against DNA damage-induced cell death
- SO Developmental Brain Research (2001), 131(1,2), 167-171 CODEN: DBRRDB; ISSN: 0165-3806
- L6 ANSWER 29 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN
- AU Okano, Hideyuki; Sakakibara, Shin-ichi; Sawamoto, Kazunobu; Nakamura, Yuki; Kaneko, Yukiko; Akamatsu, Wado; Tokunaga, Akinori; Imai, Takao; Miyata, Takaki; Shimazaki, Takuya
- TI Regulatory mechanisms for the differentiation of neural stem cells
- SO International Congress Series (2001), 1222(Tissue Engineering for Therapeutic Use 5), 11-19
 CODEN: EXMDA4; ISSN: 0531-5131
- L6 ANSWER 30 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN
- IN Eriksson, Peter; Orwar, Owe
- TI A method for introducing nucleic acids into **neural** stem or **progenitor cells** via the inherent transport system of the cell
- SO PCT Int. Appl., 26 pp. CODEN: PIXXD2
- L6 ANSWER 31 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN
- IN Eriksson, Peter
- TI Growth hormone-modulating agents and method for treatment of conditions affecting neural stem cells or progenitor cells
- SO PCT Int. Appl., 22 pp. CODEN: PIXXD2
- L6 ANSWER 32 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN
- IN Snyder, Evan Y.; Lynch, William P.; Breakefield, Xandra O.; Aboody, Karen
- TI Engraftable neural progenitor and stem cells for brain tumor therapy
- SO PCT Int. Appl., 33 pp. CODEN: PIXXD2
- L6 ANSWER 33 OF 47 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
- AU Peterson, Daniel A. [Reprint author]; Ray, Jasodhara; Gage, Fred H.
- TI Future prospects of gene therapy for treating CNS diseases.
- SO Emerich, Dwaine F. [Editor]; Dean, Reginald L., III [Editor]; Sanberg, Paul R. [Editor]. (2000) pp. 485-508. Contemporary Neuroscience. Central nervous system diseases: Innovative animal models from lab to clinic. print.
 - Publisher: Humana Press Inc., 999 Riverview Drive, Suite 208, Totowa, NJ, 07512, USA.
 - ISBN: 0-89603-724-X (cloth).
- L6 ANSWER 34 OF 47 MEDLINE on STN DUPLICATE 7
- AU Benedetti S; Pirola B; Pollo B; Magrassi L; Bruzzone M G; Rigamonti D;

- Galli R; Selleri S; Di Meco F; De Fraja C; Vescovi A; Cattaneo E; Finocchiaro G
- TI Gene therapy of experimental brain tumors using neural progenitor cells.
- SO Nature medicine, (2000 Apr) 6 (4) 447-50. Journal code: 9502015. ISSN: 1078-8956.
- L6 ANSWER 35 OF 47 MEDLINE on STN DUPLICATE 8
- AU Kaneko Y; Sakakibara S; Imai T; Suzuki A; Nakamura Y; Sawamoto K; Ogawa Y; Toyama Y; Miyata T; Okano H
- TI Musashil: an evolutionally conserved marker for CNS progenitor cells including neural stem cells.
- SO Developmental neuroscience, (2000) 22 (1-2) 139-53. Journal code: 7809375. ISSN: 0378-5866.
- L6 ANSWER 36 OF 47 MEDLINE on STN DUPLICATE 9
- AU Okano H
- TI Neural stem cells: the basic biology and prospects for brain repair.
- SO Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, (2000 Feb) 20 (1) 21-6. Ref: 35 Journal code: 9509023. ISSN: 1340-2544.
- L6 ANSWER 37 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN
- IN Reid, James Steven; Fallon, James H.
- TI Methods for treating neurological deficits
- SO PCT Int. Appl., 100 pp. CODEN: PIXXD2
- L6 ANSWER 38 OF 47 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
- AU Alder J; Lee K J; Jessell T M; Hatten M E (Reprint)
- TI Generation of cerebellar granule neurons in vivo by transplantation of BMP-treated neural progenitor cells
- SO NATURE NEUROSCIENCE, (JUN 1999) Vol. 2, No. 6, pp. 535-540.
 Publisher: NATURE AMERICA INC, 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707.
 ISSN: 1097-6256.
- L6 ANSWER 39 OF 47 MEDLINE ON STN DUPLICATE 10
- AU Shihabuddin L S; Palmer T D; Gage F H
- TI The search for neural progenitor cells: prospects for the therapy of neurodegenerative disease.
- SO Molecular medicine today, (1999 Nov) 5 (11) 474-80. Ref: 35 Journal code: 9508560. ISSN: 1357-4310.
- L6 ANSWER 40 OF 47 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
- AU Muir J K; Raghupathi R; Saatman K E; Wilson C A; Lee V M Y; Trojanowski J Q; Philips M F; McIntosh T K (Reprint)
- TI Terminally differentiated human neurons survive and integrate following transplantation into the traumatically injured rat brain
- SO JOURNAL OF NEUROTRAUMA, (MAY 1999) Vol. 16, No. 5, pp. 403-414.
 Publisher: MARY ANN LIEBERT INC PUBL, 2 MADISON AVENUE, LARCHMONT, NY 10538.
 ISSN: 0897-7151.
- L6 ANSWER 41 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN
- AU Qureshi, Nazer H.; Chiocca, E. Antonio
- TI A review of gene therapy for the treatment of central nervous system tumors
- SO Critical Reviews in Oncogenesis (1999), 10(4), 261-274 CODEN: CRONEI; ISSN: 0893-9675
- L6 ANSWER 42 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN
- AU Milward, Elizabeth A.; Lundberg, Cathryn G.; Ge, Bin; Lipsitz, David; Zhao, Ming; Duncan, Ian D.

- TI Isolation and transplantation of multipotential populations of epidermal growth factor-responsive, neural progenitor cells from the canine brain
- SO Journal of Neuroscience Research (1997), 50(5), 862-871 CODEN: JNREDK; ISSN: 0360-4012
- L6 ANSWER 43 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN
- AU Sakuragawa, Norio
- TI Hereditary metabolic disease with convulsion and therapeutic approach
- SO Igaku no Ayumi (1997), 183(1), 43-47 CODEN: IGAYAY; ISSN: 0039-2359
- L6 ANSWER 44 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN
- IN Cauley, Keith; Kukekov, Valery G.
- TI Human oligodendroglial progenitor cell line, exogenous gene expression, and use for gene therapy or neuropharmaceutical drug discovery
- SO PCT Int. Appl., 41 pp. CODEN: PIXXD2
- L6 ANSWER 45 OF 47 MEDLINE on STN
- AU Kahn A; Haase G; Akli S; Guidotti J E
- TI [Gene therapy of neurological diseases].

 Therapie genique des maladies neurologiques.
- SO Comptes rendus des seances de la Societe de biologie et de ses filiales, (1996) 190 (1) 9-11.

 Journal code: 7505439. ISSN: 0037-9026.
- L6 ANSWER 46 OF 47 MEDLINE ON STN DUPLICATE 11
- AU Kesari S; Randazzo B P; Valyi-Nagy T; Huang Q S; Brown S M; MacLean A R; Lee V M; Trojanowski J Q; Fraser N W
- TI Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant.
- SO Laboratory investigation; a journal of technical methods and pathology, (1995 Nov) 73 (5) 636-48.

 Journal code: 0376617. ISSN: 0023-6837.
- L6 ANSWER 47 OF 47 MEDLINE on STN DUPLICATE 12
- AU Snyder E Y; Taylor R M; Wolfe J H
- TI Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain.
- SO Nature, (1995 Mar 23) 374 (6520) 367-70. Journal code: 0410462. ISSN: 0028-0836.

```
=> s hib5(w)cell
L1 108 HIB5(W) CELL

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2 53 DUP REM L1 (55 DUPLICATES REMOVED)
```

=> d bib ab 1-10 12

- L2 ANSWER 1 OF 53 MEDLINE on STN DUPLICATE 1
- AN 2004023089 MEDLINE
- DN PubMed ID: 14720513
- TI Induction of neurites by the regulatory domains of PKCdelta and epsilon is counteracted by PKC catalytic activity and by the RhoA pathway.
- AU Ling Mia; Troller Ulrika; Zeidman Ruth; Lundberg Cecilia; Larsson Christer
- CS Department of Laboratory Medicine, Molecular Medicine, Lund University, Malmo University Hospital, 205 02 Malmo, Sweden.
- SO Experimental cell research, (2004 Jan 1) 292 (1) 135-50. Journal code: 0373226. ISSN: 0014-4827.
- CY United States
- DT Journal; Article; (JOURNAL ARTICLE)
- LA English
- FS Priority Journals
- EM 200402
- ED Entered STN: 20040115 Last Updated on STN: 20040302 Entered Medline: 20040227
- AΒ We have shown that protein kinase C (PKC) epsilon, independently of its kinase activity, via its regulatory domain (RD), induces neurites in neuroblastoma cells. This study was designed to evaluate whether the same effect is obtained in nonmalignant neural cells and to dissect mechanisms mediating the effect. Overexpression of PKCepsilon resulted in neurite induction in two immortalised neural cell lines (HiB5 and RN33B). Phorbol ester potentiated neurite outgrowth from PKCepsilon-overexpressing cells and led to neurite induction in cells overexpressing PKCdelta. The effects were potentiated by blocking the PKC catalytic activity with GF109203X. Furthermore, kinase-inactive PKCdelta induced more neurites than the wild-type isoform. The isolated regulatory domains of novel PKC isoforms also induced neurites. Experiments with PKCdelta-overexpressing HiB5 cells demonstrated that phorbol ester, even in the presence of a PKC inhibitor, led to a decrease in stress fibres, indicating an inactivation of RhoA. Active RhoA blocked PKC-induced neurite outgrowth, and inhibition of the RhoA effector ROCK led to neurite outgrowth. This demonstrates that neurite induction by the regulatory domain of PKCdelta can be counteracted by PKCdelta kinase activity, that PKC-induced neurite outgrowth is accompanied by stress fibre dismantling indicating an inactivation of RhoA, and that the RhoA pathway suppresses PKC-mediated neurite outgrowth.
- L2 ANSWER 2 OF 53 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
- AN 2004:104585 BIOSIS
- DN PREV200400096191
- TI Low-level tyrosine hydroxylase (TH) expression allows for the generation of stable TH+ cell lines of human neural stem cells.
- AU Liste, Isabel; Navarro, Beatriz; Johansen, Jens; Bueno, Carlos; Villa, Ana; Johansen, Teit E.; Martinez-Serrano, Alberto [Reprint Author]
- CS Center of Molecular Biology Severo Ochoa, Department of Molecular Biology, Autonomous University of Madrid, Campus Cantoblanco, Madrid, 28049, Spain amserrano@cbm.uam.es
- SO Human Gene Therapy, (January 2004) Vol. 15, No. 1, pp. 13-20. print. ISSN: 1043-0342 (ISSN print).
- DT Article
- LA English

ED Entered STN: 18 Feb 2004 Last Updated on STN: 18 Feb 2004

Genetic engineering of neurotransmitter metabolic routes is important for AB the development of neurotransmitter-producing cells for the ex vivo gene therapy of many CNS diseases. Human neural stem cells (hNSCs) are excellent candidates to serve this role, but, for the case of Parkinson's disease, the cells do not normally express the rate-limiting dopamine (DA) synthesis enzyme tyrosine hydroxylase (TH), and are not equipped with the detoxifying mechanisms needed to prevent the neurotoxicity associated with the DA phenotype. In this study we have examined the capacity of hNSCs for ectopic expression of human TH. High-level TH expression (from viral promoters) leads to growth arrest and hNSC death (associated with an increase in p53 expression and nuclear fragmentation), which can be counteracted by treatment with a pan-caspase inhibitor. As a consequence, stable TH-expressing hNSC sublines could not be derived using viral promoters. In contrast, moderate TH expression (from a human housekeeping promoter, polyubiquitin gene), allows for stable TH+ subclone derivation, seemingly originating from low-expressing cells. Our results are thus compatible with the view that stable TH-expressing hNSC lines can be generated if TH expression levels are kept at a moderate level, and that the goal normally set of aiming at high-level TH expression may need to be reconsidered. These results may be relevant for the generation of THJDA-producing human neural cells for in vitro and neurotransplantation research in Parkinson's disease.

L2 ANSWER 3 OF 53 MEDLINE on STN

DUPLICATE 2

AN 2003580075 IN-PROCESS

DN PubMed ID: 14661183

- TI Increased in vitro and in vivo transgene expression levels mediated through cis-acting elements.
- AU Johansen Jens; Tornoe Jens; Moller Arne; Johansen Teit E
- CS NsGene A/S, Ballerup, Denmark.. jjha@lundbeck.com
- SO journal of gene medicine, (2003 Dec) 5 (12) 1080-9. Journal code: 9815764. ISSN: 1099-498X.
- CY England: United Kingdom
- DT Journal; Article; (JOURNAL ARTICLE)
- LA English
- FS IN-PROCESS; NONINDEXED; Priority Journals
- ED Entered STN: 20031216
 - Last Updated on STN: 20040107

BACKGROUND: Gene therapy for neurodegenerative diseases depends critically AB on the vector system to direct sustained and stable expression of the transgene. It is, however, a commonly observed phenomenon that transgene expression from currently available vectors is down-regulated following ex vivo gene transfer to the central nervous system (CNS). In an attempt to circumvent this problem, we have systematically evaluated the potential of different cis-acting elements to increase and stabilize transgene expression in vitro and after grafting of engineered cell lines to the CNS. METHODS: Plasmid vector constructs incorporating Woodchuck hepatitis post-transcriptional regulatory element (WPRE), cHS4 insulator elements and/or the translational enhancer element SP163 were produced. Stable, polyclonal cultures of HiB5 cells were generated by transfection with reporter constructs, and in vitro transgene mRNA and protein levels were determined. Finally, HiB5 clones engineered to express the enhanced green fluorescent protein (EGFP) were grafted to the rat striatum and expression levels were evaluated. RESULTS: Inserting the WPRE element downstream of the open reading frame (ORF) of a reporter gene and flanking the transcriptional unit with cHS4 insulator elements significantly increased protein and mRNA expression levels. Surprisingly, the SP163 element, previously reported to be a translational enhancer, apparently did not promote any translational enhancing activity. Furthermore, the SP163 element exerted a negative effect on transcription. The ability of cHS4 and WPRE elements to stabilize in vivo transgene expression was demonstrated by transplantation of HiB5 clones containing

expression constructs into the rat striatum. CONCLUSION: The data suggest that incorporating cis-acting elements in gene therapy vectors may result in improvements to currently available therapeutic vectors. Copyright 2003 John Wiley & Sons, Ltd.

- L2 ANSWER 4 OF 53 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
- AN 2004:86901 BIOSIS
- DN PREV200400089734
- TI The basic helix-loop-helix transcription factor TAL1/SCL inhibits the expression of the p16INK4A and pTalpha genes.
- AU Hansson, Anders; Manetopoulos, Christina; Jonsson, Jan-Ingvar; Axelson, Hakan [Reprint Author]
- CS Department of Laboratory Medicine, Division of Molecular Medicine, Lund University, University Hospital MAS, SE-205 02, Malmo, Sweden hakan.axelson@molmed.mas.lu.se
- SO Biochemical and Biophysical Research Communications, (December 26 2003) Vol. 312, No. 4, pp. 1073-1081. print. CODEN: BBRCA9. ISSN: 0006-291X.
- DT Article
- LA English
- ED Entered STN: 11 Feb 2004 Last Updated on STN: 11 Feb 2004
- The Tall gene (also called Scl or TCL5) encodes a basic helix-loop-helix AΒ transcription factor required for hematopoiesis and vasculogenesis. Additionally, aberrant transcriptional activation of the Tall gene is a frequent event in human T cell acute lymphoblastic leukemia (T-ALL). T cell specific expression of TAL1 in mice induces aggressive T cell malignancies, demonstrating the oncogenic potential of TAL1. Yet, the underlying mechanisms of TAL1 induced tumorigenesis are poorly understood. By inhibiting E protein mediated transcription of the pTalpha gene, TAL1 can interfere with the T cell differentiation program. In addition, several studies suggest that TAL1 expression might also enhance proliferation rate. We report here that TAL1 can bind the E boxes in both the p16 and the pTalpha promoters, and functionally suppress the activity of both promoters. These results indicate that TAL1 can affect both T cell proliferation and differentiation. Moreover, we show that overexpression of TAL1 in hematopoietic progenitor cells promotes cell cycle division.
- L2 ANSWER 5 OF 53 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
- AN 2003:477660 BIOSIS
- DN PREV200300477660
- TI The Lim-only protein LMO4 modulates the transcriptional activity of HEN1.
- AU Manetopoulos, Christina; Hansson, Anders; Karlsson, Jenny; Jonsson, Jan-Ingvar; Axelson, Hakan [Reprint Author]
- CS Department of Laboratory Medicine, Division of Molecular Medicine, Lund University, University Hospital MAS, Malmo, S-205 02, Sweden hakan.axelson@molmed.mas.lu.se
- SO Biochemical and Biophysical Research Communications, (August 8 2003) Vol. 307, No. 4, pp. 891-899. print. CODEN: BBRCA9. ISSN: 0006-291X.
- DT Article
- LA English
- ED Entered STN: 15 Oct 2003 Last Updated on STN: 15 Oct 2003
- The basic helix-loop-helix protein HEN1 and the LIM-only proteins LMO2 and LMO4 are expressed in neuronal cells. HEN1 was cloned by virtue of its homology to TAL1, a bHLH protein important for early hematopoiesis. Since it has been shown that TAL1 forms complex with LMO proteins in erythroid and leukemic cells we investigated the capacity of HEN1 to form complex with LMO2 and LMO4. By mammalian two-hybrid analysis, we show that HEN1 interacts with both LMO2 and LMO4. To characterize the transcriptional capacity of HEN1 alone or together with LMO2 and LMO4, we performed reporter gene assays. In comparison with the ubiquitously expressed bHLH

protein E47, HEN1 is a very modest transcriptional activator and titration experiments indicate that HEN1, like TAL1, represses E47 mediated transcriptional activation. Furthermore, LMO4 but not LMO2 was able to augment this effect. Overexpression of HEN1 in hippocampal precursor cells resulted in neurite extension, which could be prevented by LMO4. Taken together, these results indicate that LMO proteins can modulate the transcriptional activity of HEN1.

DUPLICATE 3

- L2 ANSWER 6 OF 53 MEDLINE on STN
- AN 2004001101 IN-PROCESS
- DN PubMed ID: 14696671
- TI Protective effect of shenqi-wan against H2O2-induced apoptosis in hippocampal neuronal cells.
- AU Shin Hyun-Taeg; Chung Seok-Hee; Lee Jong-Soo; Kim Sung-Soo; Shin Hyun-Dae; Jang Mi-Hyeon; Shin Min-Chul; Bahn Geon-Ho; Paik Eun-Kyung; Park Jae-Hyung; Kim Chang-Ju
- CS Department of Oriental Rehabilitation Medicine, College of Oriental Medicine Kyung Hee University, Seoul, Korea.
- SO American journal of Chinese medicine, (2003) 31 (5) 675-86. Journal code: 7901431. ISSN: 0192-415X.
- CY United States
- DT Journal; Article; (JOURNAL ARTICLE)
- LA English
- FS IN-PROCESS; NONINDEXED; Priority Journals
- ED Entered STN: 20040106 Last Updated on STN: 20040106
- The present study investigated whether Shenqi-wan possesses a protective effect against hydrogen peroxide (H2O2)-induced apoptosis of the hippocampal cell line HiB5. Through morphological and biochemical analyses, it was demonstrated that HiB5 cells treated with H2O2 exhibited several apoptotic features, while cells pre-treated with Shenqi-wan prior to H2O2 exposure showed a decrease in the occurrence of apoptosis. In addition, a patch clamp study revealed that Shenqi-wan inhibited profoundly N-methyl-D-aspartic acid (NMDA) receptor-activated ion current in acutely dissociated hippocampal CA1 neurons. These results suggest that Shenqi-wan may exert its protective effect against H2O2-induced apoptosis via inhibition of NMDA receptors in hippocampal neuronal cells.
- L2 ANSWER 7 OF 53 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
- AN 2004:173400 BIOSIS
- DN PREV200400174684
- TI Nonspecific association of 2',3'-cyclic nucleotide 3'-phosphodiesterase with the rat forebrain postsynaptic density fraction.
- AU Cho, Sun-Jung; Jung, Jae Seob; Shin, Seung Chul; Jin, Ingnyol; Ko, Bok Hyun; Kwon, Yunhee Kim; Suh-Kim, Haeyoung; Moon, Il Soo [Reprint Author]
- CS Department of Anatomy, College of Medicine, Medical Institute of Dongguk University, Gyeongju, 780-714, South Korea moonis@dongguk.ac.kr
- SO Experimental & Molecular Medicine, (December 31 2003) Vol. 35, No. 6, pp. 486-493. print.
 ISSN: 1226-3613.
- DT Article
- LA English
- ED Entered STN: 31 Mar 2004 Last Updated on STN: 31 Mar 2004
- AB The 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), a protein of unknown function in vivo, is abundantly expressed in myelinating glia in two isoforms, CNP1 and CNP2. In this study, immunoblot analysis showed that CNP1 is the major isoform in adult forebrain, and that both isoforms are included in the postsynaptic density (PSD) fraction and tyrosine-phosphorylated at the basal level. However, subcellular distribution and detergent extraction data showed that CNP is nonspecifically associated with the PSD fraction. Immunocytochemistry

revealed that CNP is detected, in a weak but punctate pattern, in dissociated rat hippocampal neurons of 3 days to 2 weeks in vitro. The CNP-positive punctae were distributed throughout soma and dendrites, and distinct from PSD95-positive ones. Immunoblot analysis indicated that CNP is also expressed in neuronal stern cell lines, HiB5 and F11. Interestingly, in addition to the known two isoforms, a new CNP isoform of MW 45 kDa was expressed in these cell lines and was the major type of isoform in F11 cells. Taken together, our data suggest that CNP is expressed in the early stage of in vitro development and nonspecifically included in the adult rat PSD fraction.

- L2 ANSWER 8 OF 53 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 4
- AN 2003:483922 CAPLUS
- DN 139:114740
- TI The effect of brain-derived neurotrophic factor on neuritogenesis and synaptic plasticity in Aplysia neurons and the hippocampal cell line HiB5
- AU Lee, Seung-Hee; Han, Jin-Hee; Choi, Jung-Hwan; Huh, Eun-Young; Kwon, Yunhee Kim; Kaang, Bong-Kiun
- CS National Research Laboratory of Neurobiology, Institute of Molecular Biology and Genetics, School of Biological Sciences, Seoul National University, Seoul, 151-742, S. Korea
- SO Molecules and Cells (2003), 15(2), 233-239 CODEN: MOCEEK; ISSN: 1016-8478
- PB Korean Society for Molecular and Cellular Biology
- DT Journal
- LA English
- AΒ Brain-derived neurotrophic factor (BDNF) plays a key role in the differentiation and neuritogenesis of developing neurons, and in the synaptic plasticity of mature neurons, in the mammalian nervous system. BDNF binds to the receptor tyrosine kinase TrkB and transmits neurotrophic signals by activating neuron-specific tyrosine phosphorylation pathways. However, the neurotrophic function of BDNF in Aplysia neurons is poorly understood. The authors examined the specific effect of BDNF on neurite outgrowth and synaptic plasticity in cultured Aplysia neurons and a multipotent rat hippocampal stem cell line (HiB5). The authors' study indicates that mammalian BDNF has no significant effect on the neuritogenesis, neurotransmitter release, excitability, and synaptic plasticity of cultured Aplysia neurons in the authors' exptl. conditions. In contrast, BDNF in combination with platelet-derived growth factor (PDGF) increases the length of the neurites and the number of spine-like structures in cells of HiB5.
- RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT
- L2 ANSWER 9 OF 53 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
- AN 2004:205324 BIOSIS
- DN PREV200400205851
- TI Upregulation of beta Pix expression in migrating neural stem cells in the rat brain.
- AU Huh, E. [Reprint Author]; Yoon, J. [Reprint Author]; Lim, J. [Reprint Author]; Park, D.; Chung, J.; Kwon, Y. K. [Reprint Author]
- CS Dept. of Biol., Kyunghee Univ, Seoul, South Korea
- So Society for Neuroscience Abstract Viewer and Itinerary Planner, (2003) Vol. 2003, pp. Abstract No. 885.9. http://sfn.scholarone.com. e-file. Meeting Info.: 33rd Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 08-12, 2003. Society of Neuroscience.
- DT Conference; (Meeting)
 - Conference; Abstract; (Meeting Abstract)
- LA English
- ED Entered STN: 14 Apr 2004
 - Last Updated on STN: 14 Apr 2004
- AB The small GTPases of the Rho family play roles in transducing extracellular stimuli into distinct responses including cell motility, adhesion, cell division and phagocytosis. The GTPases cycle between

GTP-bound and GDP-bound forms and their activation requires the action of guanine nucleotide exchange factors (GEFs) to promote the conversion of the GDP to the GTP state. beta-Pix is p21-activated kinase (PAK)-interacting exchange factor (PIX). It encodes a guanine nucleotide exchange factor for Rho guanosisne triphosphatases (Rac/Cdc42) and known to regulate actin cytoskeleton reorganization, cooperating with Rac, PAK and GIT. It contains SH3 (Src homology 3), DH(Dbl homology), PH(Pleckstrin homology) , PXXP, Insert region domain. HiB5 cells are neuronal stem cells derived from embryonic day16 (E16) rat hippocampus. PDGF treated HiB5 cells migrate along hippocampal alveus by 4weeks when transplanted into the rat hippocampus. We investigated whether the migrating neural stem cells express beta-pix. Isoforms of beta-Pix were detected in HiB5 cells using antibody raised against beta-Pix insert domain. PDGF treated HiB5 cells migrating along hippocampal alveus increasd expression of beta-Pix and paxillin than PDGF untreated HiB5 cells. The result of this study suggest that PDGF enhances migration of transplanted HiB5 cells and beta-Pix regulates migration and differentiation.

```
L2
     ANSWER 10 OF 53 CAPLUS COPYRIGHT 2004 ACS on STN
AN
     2002:31496 CAPLUS
DN
     136:65968
TI
     A lamotrigine-sensitive sodium channel RNAv1.5a from rat astrocytes
IN
     Korsgaard, Mads P. G.
PΑ
     Neurosearch A/s, Den.
SO
     PCT Int. Appl., 12 pp.
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 1
     PATENT NO. KIND DATE
                                         APPLICATION NO. DATE
     -----
                                         -----
                          _____
PΙ
    WO 2002002608 A2 20020110
                                          WO 2001-DK414 20010614
     WO 2002002608
                     A3 20020510
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
            HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
            LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
            SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
            YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1301596
                     A2 20030416
                                        EP 2001-940247 20010614
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRAI DK 2000-1049
                           20000705
                     Α
    WO 2001-DK414
                      W
                           20010614
    The present invention relates to a novel voltage gated sodium channel
AB
    located in the brain, a cDNA encoding it, vectors and host cells containing
    the same, transgenic non-human animal capable of expressing the sodium
    channel, and methods of screening for modulators of the channel such as
    modulators for use in the treatment of seizures, and conditions related to
    the limbic system and limbic regions including limbic seizures.
    sodium channel, a sequence homolog of the rat RNAv1.5 channel was
    identified by RT-PCR during an anal. of sodium channel gene expression in
    HiB5 cells. The protein was more sensitive to
    inhibition by lamotrigine than the RNAv1.5 channel, suggesting that it may
    be a target for the treatment of epilepsy.
```

(FILE 'HOME' ENTERED AT 15:02:07 ON 14 MAY 2004) FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 15:02:23 ON 14 MAY 2004 L_1 3012 S (NEURONAL OR NEURAL) (3A) PROGENITOR (W) CELL L266482 S (TREAT? OR PROTECT?) (6A) (NEURAL(W)TISSUE OR BRAIN OR CNS OR C L3 73 S L1 AND L2 L413 S L1(9A)L2 L5 11 DUP REM L4 (2 DUPLICATES REMOVED) L6 47 DUP REM L3 (26 DUPLICATES REMOVED) => d bib ab 1-11 15 L5 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN AN 2003:376662 CAPLUS DN 138:379246 TIThe functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells Bertilsson, Goran; Frisen, Jonas; Falk, Anna; Heidrich, Jessica; INHellstrom, Kristina; Kortesmaa, Jarkko; Lindquist, Per; Lundh, Hanna; McGuire, Jaccqueline; Mercer, Alex; Patrone, Cesare; Ronnholm, Harriet; Wikstrom, Lilian; Zachrisson, Olof PA Neuronova AB, Swed. SO PCT Int. Appl., 112 pp. CODEN: PIXXD2 DТ Patent LA English FAN.CNT 1 PATENT NO. KIND DATE APPLICATION NO. DATE ----------______ WO 2003039575 A2 20030515 PΙ WO 2002-GB5078 20021111 WO 2003039575 A3 20031016 AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG US 2003165485 **A**1 20030904 US 2002-291171 20021108 PRAI US 2001-344725P Ρ 20011109 US 2001-345064P Ρ 20011109 US 2002-393263P Ρ 20020702 US 2002-394397P Р 20020708 The invention relates generally to methods of influencing central nervous AB system cells to produce progeny useful in the treatment of CNS disorders. More specifically, the invention includes methods of exposing a patient suffering from such a disorder to reagent that modulates the proliferation, migration, differentiation and survival of central nervous system cells via Reelin, Gas6 or Protein S signaling. These methods are useful for reducing at least one symptom of the disorder. L5ANSWER 2 OF 11 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN 2003:554377 SCISEARCH ANThe Genuine Article (R) Number: 692TP GΑ TINitric oxide acts in a positive feedback loop with BDNF to regulate neural

progenitor cell proliferation and differentiation in the mammalian brain

- AU Cheng A W; Wang S Q; Cai J L; Rao M S; Mattson M P (Reprint)
- CS NIA, Gerontol Res Ctr, Neurosci Lab, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA (Reprint); NIA, Gerontol Res Ctr, Neurosci Lab, Baltimore, MD 21224 USA
- CYA USA
- SO DEVELOPMENTAL BIOLOGY, (15 JUN 2003) Vol. 258, No. 2, pp. 319-333. Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA. ISSN: 0012-1606.
- DT Article; Journal
- LA English
- REC Reference Count: 62
 - *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
- AB Nitric oxide (NO) is believed to act as an intercellular signal that regulates synaptic plasticity in mature neurons. We now report that NO also regulates the proliferation and differentiation of mouse brain neural progenitor cells

(NPCs). Treatment of dissociated mouse cortical neuroepithelial cluster cell cultures with the NO synthase inhibitor L-NAME or the NO scavenger hemoglobin increased cell proliferation and decreased differentiation of the NPCs into neurons, whereas the NO donor sodium nitroprusside inhibited NPC proliferation and increased neuronal differentiation. Brain-derived neurotrophic factor (BDNF) reduced NPC proliferation and increased the expression of neuronal NO synthase (nNOS) in differentiating neurons. The stimulatory effect of BDNF on neuronal differentation of NPC was blocked by L-NAME and hemoglobin, suggesting that NO produced by the latter cells inhibited proliferation and induced neuronal differentiation of neighboring NPCs. A similar role for NO in regulating the switch of neural stem cells from proliferation to differentiation in the adult brain is suggested by data showing that NO synthase inhibition enhances NPC proliferation and inhibits neuronal differentiation in the subventricular zone of adult mice. These findings identify NO as a paracrine messenger stimulated by neurotrophin signaling in newly generated neurons to control the proliferation and differentiation of NPC, a novel mechanism for the regulation of developmental and adult neurogenesis. (C) 2003 Elsevier Science (USA). All rights reserved.

DUPLICATE 1

- L5 ANSWER 3 OF 11 MEDLINE on STN
- AN 2003287176 MEDLINE
- DN PubMed ID: 12814945
- TI Differentiation and morphological integration of neural progenitor cells transplanted into the developing mammalian eye.
- AU Sakaguchi D S; Van Hoffelen S J; Young M J
- CS Department of Zoology and Genetics, Iowa State University, Ames, Iowa 50011, USA. dssakagu@iastate.edu
- NC 09595
- SO Annals of the New York Academy of Sciences, (2003 May) 995 127-39. Ref: 26
 - Journal code: 7506858. ISSN: 0077-8923.
- CY United States
- DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
- LA English
- FS Priority Journals
- EM 200307
- ED Entered STN: 20030620 Last Updated on STN: 20030723
 - Entered Medline: 20030722
- AB Transplantation of neural stem/progenitor cells has been proposed as a novel approach for the replacement and repair of damaged CNS tissues. We have evaluated the influence of the host cellular microenvironment upon the survival, differentiation, and integration of neural progenitor cells

transplanted into the CNS. Using this approach, we have investigated the fate of neural progenitor cells in vivo following transplantation into the developing mammalian eye. Murine brain progenitor cells (mBPCs) isolated from neonatal mice expressing the green fluorescent protein (GFP) transgene were transplanted into the eyes of Brazilian opossums (Monodelphis domestica). Monodelphis pups are born in an extremely immature, fetal-like state. The eyes of neonatal pups provide a fetal-like environment in which to study cellular interactions between host tissues and transplanted neural progenitor cells. mBPCs were transplanted by intraocular injection in hosts ranging in age from 5 days postnatal to adult. The transplanted cells were easily identified because of their GFP fluorescence. Extensive survival, differentiation, and morphological integration of mBPCs within the host tissue was observed. We found that the younger retinas provided a more supportive environment for the morphological integration of the transplanted mBPCs. Cells with morphologies characteristic of specific retinal cell types were observed. Moreover, some transplanted mBPCs were labeled with antibodies characteristic of specific neural/retinal phenotypes. These results suggest that the host environment strongly influences progenitor cell differentiation and that transplantation of neural progenitor cells may be a useful approach aimed at treating degeneration and pathology of the CNS.

- L5 ANSWER 4 OF 11 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
- AN 2004:194632 BIOSIS
- DN PREV200400195191
- TI Transplantation of neural progenitor cells and fibroblasts into motor cortex and striatum of naive rats: Survival, migration, differentiation, and functional outcome.
- AU Price, R. O. [Reprint Author]; Pedatella, K. E. [Reprint Author]; Schallert, T. J.; Palmer, T. D. [Reprint Author]
- CS Neurosurgery, Stanford Univ., Stanford, CA, USA
- SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2003) Vol. 2003, pp. Abstract No. 150.10. http://sfn.scholarone.com. e-file. Meeting Info.: 33rd Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 08-12, 2003. Society of Neuroscience.
- DT Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
- LA English
- ED Entered STN: 14 Apr 2004
- Last Updated on STN: 14 Apr 2004

 AB Neural progenitor cells (NPCs) are being

investigated as a treatment modality for various brain pathologies but the precise role NPCs play in functional recovery remains unclear. The goal of this study is to examine cellular behavior and the effects of cell transplantation on motor function in the healthy brain. NPCs were compared with skin fibroblasts (1X105 cells/mul) or saline. Cells were pre-labeled with bromodeoxyuridine (BrdU) and stereotaxically injected into the putamen and primary motor cortex of adult rats. One cell type was placed in the left hemisphere and saline, or the opposite cell type, placed in the right hemisphere. Sensory and motor behavior in the vertical exploration, ledged-tapered beam, and adhesive-removal paradigms were assessed for 28 days post-transplant. The brains were removed and evaluated for cell survival, migration, and fate. Behavioral data suggest that NPCs produce an asymmetry in forelimb use (increase in use of the forelimb opposite to the NPC transplants) when saline-only was transplanted in the contralateral hemisphere. Fibroblasts transplanted contralateral to the NPCs appear to negate the asymmetry. Histologically, NPCs migrate extensively and differentiate variably depending upon the distance from the graft and location within the brain. In contrast, fibroblasts have reduced survival and do not migrate. In these pilot studies, it appears that NPCs and fibroblast transplants can influence behavior, but the effects on motor function may be independent of cell source, extent of migration, or phenotype of surviving cells.

- ANSWER 5 OF 11 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN L_5
- AN 2002:26101 SCISEARCH
- The Genuine Article (R) Number: 505CY GA
- TI Stem cells in neurodevelopment and plasticity
- Vaccarino F M (Reprint); Ganat Y; Zhang Y C; Zheng W ΑU
- Yale Univ, Ctr Child Study, 230 S Frontage Rd, New Haven, CT 06520 USA CS (Reprint); Yale Univ, Ctr Child Study, New Haven, CT 06520 USA; Yale Univ, Neurobiol Sect, New Haven, CT 06520 USA
- CYA
- NEUROPSYCHOPHARMACOLOGY, (DEC 2001) Vol. 25, No. 6, pp. 805-815. SO Publisher: ELSEVIER SCIENCE INC, 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA.
 - ISSN: 0893-133X.
- DTGeneral Review; Journal
- English LA
- Reference Count: 100 REC
 - *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
- The processes of stem cell proliferation and differentiation during AB embryogenesis are governed by transcription factors that regulate the regional differentiation of the central nervous system (CNS). Do neural "stem" cells persisting in the postnatal CNS disobey this sequence of events? The division of neural progenitor cells is promoted by basic Fibroblast Growth Factor Fgf2 or Epidermal Growth Factor Egf. However, while the intraventricular administration of FgF2 during embryogenesis increases the generation of cortical pyramidal neurons, the same treatment in the adult CNS produces interneurons of the olfactory bulb. The competence of neural progenitor cells to respond to Fqf is dictated by nuclear transcription factors that constrain neuronal fates through time. Developmentally regulated transcriptional programs are regulated by cell interactions, as dividing cells check their molecular signature against that of their environment. Thus, cell surface interactions account for competitive phenomena among pools of cells, including the inhibitory effect of neurons on the division of their progenitors, and may also explain the "permissive" effects of non-CNS environments. The challenge remains to understand the genetic programs that control the fate of progenitor cells within the postnatal CNS and their regulation by stress, apoptosis and environmental perturbations. These programs are likely to be similar to gene cascades that control proliferation, differentiation and migration of progenitor cells at earlier stages of development. [Neuropsychopharmacology 25:805-815,2001] (C) 2001 American College of
 - Neuropsychopharmacology. Published by Elsevier Science Inc.
- ANSWER 6 OF 11 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN L5
- 2001:976110 SCISEARCH ΑN
- GA The Genuine Article (R) Number: 498QK
- Telomerase protects developing neurons against DNA damage-induced cell ΤI death
- ΑU Lu C B; Fu W M; Mattson M P (Reprint)
- NIA, Gerontol Res Ctr, Neurosci Lab, 5600 Nathan Shock Dr, Baltimore, MD CS 21224 USA (Reprint); NIA, Gerontol Res Ctr, Neurosci Lab, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205
- CYA USA
- DEVELOPMENTAL BRAIN RESEARCH, (26 NOV 2001) Vol. 131, No. 1-2, pp. SO 167-171.
 - Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS.
 - ISSN: 0165-3806.
- DTArticle; Journal
- LAEnglish
- REC Reference Count: 34
 - *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*

In mitotic cells, telomerase adds repeats of a DNA sequence (TTAGGG) to ΑB the ends of chromosomes (telomeres) thereby maintaining their length and preventing cellular senescence. We recently reported that the catalytic subunit of telomerase (TERT) is expressed in neuronal progenitor cells and in early postmitotic neurons in the developing rodent brain. We now report that TERT can protect cultured PC12 cells and embryonic hippocampal neurons against death induced by DNA damage. Overexpression of TERT in PC12 cells increases their resistance to the topoisomerase inhibitors camptothecin and etoposide. Hippocampal neurons in which TERT levels are decreased using antisense technology exhibit increased vulnerability to the DNA-damaging agents. Emerging findings suggest that DNA damage may trigger the death of neurons during brain development and in neurodegenerative disorders. Our data therefore suggest roles for TERT in modulating such cell deaths. Published by Elsevier Science B.V.

```
L5 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
```

AN 2001:258284 CAPLUS

DN 134:364662

TI Regulatory mechanisms for the differentiation of neural stem cells

AU Okano, Hideyuki; Sakakibara, Shin-ichi; Sawamoto, Kazunobu; Nakamura, Yuki; Kaneko, Yukiko; Akamatsu, Wado; Tokunaga, Akinori; Imai, Takao; Miyata, Takaki; Shimazaki, Takuya

CS Department of Neuroanatomy CREST, JST, Osaka University Medical School, Osaka, Japan

SO International Congress Series (2001), 1222 (Tissue Engineering for Therapeutic Use 5), 11-19
CODEN: EXMDA4; ISSN: 0531-5131

PB Elsevier Science B.V.

DT Journal

LA English

Neural stem cells (NSCs) are self-renewing and multipotential neural progenitor cells, which have received considerable attention as potential tools for treating the injured or diseased brain. To develop therapeutic strategies intended to capitalize upon the plasticity and propagative ability of NSCs, we need both to better understand their biol. and to develop better means for their prospective identification and harvest. Here we report several new findings from our labs. that address the isolation of NSCs, as well as the maintenance and regulatory control of the stem cell phenotype. Specifically, we report (1) the identification of Hes 1 as a neg. regulator of NSC differentiation, and (2) the identification of the Musashi and Hu proteins as selective markers for NSCs and their neuronal daughters, resp.

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
L5 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:493693 CAPLUS
DN 133:100460
TI A method for introducing nucleic acids into neural ste
```

TI A method for introducing nucleic acids into neural stem or progenitor cells via the inherent transport system of the cell

IN Eriksson, Peter; Orwar, Owe

PA A+ Science Invest AB, Swed.

SO PCT Int. Appl., 26 pp. CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2000042202 A1 20000720 WO 2000-SE73 20000114

PI WO 2000042202 A1 20000720 WO 2000-SE73 20000114

W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,

CU, CZ, CZ, DE, DE, DK, DK, DM, EE, EE, ES, FI, FI, GB, GD, GE,

```
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR, KZ, LC,
                LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
                PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA,
                UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
           RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
                CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
      CA 2359349
                           AA 20000720
                                              CA 2000-2359349 20000114
      EP 1141340
                            A1
                                  20011010
                                                   EP 2000-902243
                                                                         20000114
           R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
                IE, SI, LT, LV, FI, RO
                           B2
                                  20020815
                                                    AU 2000-23372
                                                                         20000114
      JP 2002534126
                            T2
                                  20021015
                                                    JP 2000-593759
                                                                         20000114
                                                    NZ 2000-513502
      NZ 513502
                                  20030328
                            Α
                                                                         20000114
PRAI SE 1999-134
                            Α
                                  19990115
      WO 2000-SE73
                                  20000114
                            W
      A method for introducing a substance comprising a nucleic acid into a
AΒ
      mammalian neural stem cell or progenitor cell, characterized in that said
      nucleic acid directly interacts with the cell membrane of said cell or a
      component within said cell membrane whereby the substance comprising said
      nucleic acid is taken up by the cell via the inherent transport mechanism
      of the cell, is disclosed. The advantages of the present invention are:
      (1) it does not rely on the binding of DNA to any soluble receptors or
      carriers; (2) It allows for the selective labeling of cells, due to the
      fact that only cells with the inherent transport system are transfected.
      Also different applications of said method are disclosed.
RE.CNT 6
                 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
                 ALL CITATIONS AVAILABLE IN THE RE FORMAT
      ANSWER 9 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN
      2000:368139 CAPLUS
DN
      132:343355
TI
      Growth hormone-modulating agents and method for treatment of conditions
      affecting neural stem cells or progenitor cells
IN
      Eriksson, Peter
      A+ Science Invest AB, Swed.
PA
SO
      PCT Int. Appl., 22 pp.
      CODEN: PIXXD2
DT
      Patent
LA
      English
FAN.CNT 1
      PATENT NO.
                          KIND DATE
                                                    APPLICATION NO. DATE
                          ----
                                                    _____
PΙ
      WO 2000030675
                           A2
                                  20000602
                                                    WO 1999-SE2197
                                                                         19991125
                         A3
      WO 2000030675
                                  20000817

W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CT, CM, GA, CM, MI, MR, NE, SN, TD, TG

               CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
      EP 1135156
                           A2 20010926
                                                  EP 1999-963765
                                                                        19991125
               AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, IE, SI, LT, LV,
               FI, RO
      JP 2002530351
                            T2
                                  20020917
                                                    JP 2000-583558
                                                                         19991125
      NZ 512495
                                                    NZ 1999-512495
                            Α
                                  20031031
                                                                         19991125
PRAI SE 1998-4064
                            Α
                                  19981125
      WO 1999-SE2197
                           W
                                 19991125
      The invention discloses the use of a substance that, on administration,
AΒ
      will lead to increased concns. of growth hormone, e.g. growth hormone, a
      functionally equivalent analog thereof, or a substance that will increase the
```

release of endogenous growth hormone, for the production of a medicinal product for treatment of abnormal conditions affecting neural stem cells, progenitor cells and/or cells derived from neural stem cells or progenitor cells, especially conditions affecting the oligodendroglia, astroglia, and/or neuronal cells. In vitro and in vivo methods are disclosed for inducing lineage determination, propagating and/or inducing or maintaining the genesis

neurons, oligodendrocytes, astroglial cells from progenitor cells, stem cells and/or cells derived from said cells by administering to the cells a substance that increases the concentration of growth hormone. Also disclosed

is

of

a method of reducing the genesis of oligodendrocytes, neurons, or astroglial cells from progenitor cells or stem cells, wherein a pharmaceutically effective amount of a substance that will lead to a decreased concentration of growth hormone or a functionally equivalent analoge of

is administered to the patient.

- L5 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
- AN 1997:785588 CAPLUS
- DN 128:84693
- TI Isolation and transplantation of multipotential populations of epidermal growth factor-responsive, neural progenitor cells from the canine brain
- AU Milward, Elizabeth A.; Lundberg, Cathryn G.; Ge, Bin; Lipsitz, David; Zhao, Ming; Duncan, Ian D.
- CS Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Madison, WI, 53706, USA
- SO Journal of Neuroscience Research (1997), 50(5), 862-871 CODEN: JNREDK; ISSN: 0360-4012
- PB Wiley-Liss, Inc.
- DT Journal
- LA English
- AB Glial cell transplantation into myelin-deficient rodent models has resulted in myelination of axons and restoration of conduction velocity. The shaking (sh) pup canine myelin mutant is a useful model in which to test the ability to repair human myelin diseases, but as in humans, the canine donor supply for allografting is limited. A solution may be provided by self-renewing epidermal growth factor (EGF)-responsive multipotential neural progenitor cell populations ("neurospheres"). Nonadherent spherical clusters, similar in appearance to murine neurospheres, have been obtained from the brain of perinatal wildtype (wt) canine brain and expanded in vitro in the presence of EGF for at least 6 mo. Most of the cells in these clusters express a nestin-related protein. Within 1-2 wk after removal of EGF, cells from the clusters generate neurons, astrocytes, and both oligodendroglial progenitors and oligodendrocytes. Transplantation of lacZ-expressing wt neurospheres into the myelin-deficient (md) rat showed that a proportion of the cells differentiated into oligodendrocytes and produced myelin. In addition, cells from the neurosphere populations survived at least 6 wk after grafting into a 14-day postnatal sh pup recipient and at least 2 wk after grafting into an adult sh pup recipient. Thus, neurospheres provide a new source of allogeneic donor cells for transplantation studies in this mutant.
- RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT
- L5 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
- AN 1997:699510 CAPLUS
- DN 127:329571
- TI Hereditary metabolic disease with convulsion and therapeutic approach
- AU Sakuragawa, Norio
- CS Shinkei Kenkyusho, Kokuritsu Seishin, Shinkei Senta, Kodaira, 187, Japan
- SO Igaku no Ayumi (1997), 183(1), 43-47
 - CODEN: IGAYAY; ISSN: 0039-2359
- PB Ishiyaku

- DT Journal; General Review
- LA Japanese

=>

AB A review, with 22 refs., on mol. basis for hereditary metabolic diseases with epileptic convulsion in children including neonatal convulsion and hereditary metabolic diseases with infantile spasm. Development of neuronal progenitor cells and its grafting to the brain for the treatment are also discussed.

=> d bib 44 16

WO 1996-US8158

ANSWER 44 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN 1997:61366 CAPLUS ΑN 126:71207 DN Human oligodendroglial progenitor cell line, exogenous gene expression, TIand use for gene therapy or neuropharmaceutical drug discovery Cauley, Keith; Kukekov, Valery G. IN PΑ Signal Pharmaceuticals, Inc., USA SO PCT Int. Appl., 41 pp. CODEN: PIXXD2 Patent DT LA English FAN.CNT 1 PATENT NO. KIND DATE APPLICATION NO. DATE -----_____ -----PΙ WO 9638576 A1 19961205 WO 1996-US8158 19960530 W: AU, CA, JP RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE US 5830651 A 19981103 US 1995-458890 19950601 AU 9659590 A1 19961218 AU 1996-59590 19960530 PRAI US 1995-458890 19950601

19960530